Name: Name:Ly2334737
Brand: AABLOCKS
SKU: AA00GU1C
Rating: 90 (10 reviews)

Catalog No.: AA00GU1C

892128-60-8 | Ly2334737

Pack Size： 1mg

Purity： ≥95%

in stock

$38.00 $26.00

Pack Size： 5mg

Purity： ≥95%

in stock

$138.00 $96.00

Pack Size： 10mg

Purity： ≥95%

in stock

$256.00 $179.00

Pack Size： 25mg

Purity： ≥95%

in stock

$548.00 $383.00

Quantity

- +

Add to Card

Order Now

bulk Quotation Request

Technical Information

Catalog Number: AA00GU1C

Chemical Name: Ly2334737

CAS Number: 892128-60-8

Molecular Formula: C17H25F2N3O5

Molecular Weight: 389.3943

MDL Number: MFCD25976631

SMILES: CCCC(C(=O)Nc1ccn(c(=O)n1)[C@@H]1O[C@@H]([C@H](C1(F)F)O)CO)CCC

Properties

Complexity: 620

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 3

Heavy Atom Count: 27

Hydrogen Bond Acceptor Count: 7

Hydrogen Bond Donor Count: 3

Rotatable Bond Count: 8

XLogP3: 1.7

Downstream Synthesis Route

99-66-1

892128-60-8

[1]CurrentPatentAssignee:ELILILLY&CO-WO2006/65525,2006,A1Locationinpatent:Page/Pagecolumn5

892128-60-8

1334513-02-8

677-22-5

((S)-isopropyl2-(((S)-(((2R,3R<SUB>,</SUB>5R)-4,4-difluoro-3-hydroxy-5-(2-oxo-4-(2-propylpentanamido)pyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate)

[1]Patent:WO2015/134334,2015,A1.Locationinpatent:Paragraph00156;00158

99-66-1

4-amino-1-(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl-1,2-dihydropyrimidin-2-onehydrochloride

892128-60-8

[1]CurrentPatentAssignee:TNTMEDICALCORP;BLUEVALLEYPHARMACEUTICALLLC;TNTMEDICAL-WO2020/107013,2020,A1Locationinpatent:Page/Pagecolumn23-24

892128-60-8

22838-58-0

(2R,3R,5R)-3-(2S)-2-(tert-butoxy)carbonylamino-3-methylbutanoyloxy-4,4-difluoro-5-2-oxo-4-(2-propylpentanamido)-1,2-dihydropyrimidin-1-yloxolan-2-ylmethyl(2R)-2-(tert-butoxy)carbonylamino-3-methylbutanoate

[1]CurrentPatentAssignee:TNTMEDICALCORP;BLUEVALLEYPHARMACEUTICALLLC;TNTMEDICAL-WO2020/107013,2020,A1Locationinpatent:Page/Pagecolumn27

Literature fold

Title: Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20110915

Title: Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.

Journal: Journal of medicinal chemistry20091126

Title: Pratt SE, et al. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 2013 Mar 1;19(5):1159-68.

Title: Jialei Sun, et al. Drug Repurposing of Pyrimidine Analogs as Potent Antiviral Compounds Against Human Enterovirus A71 Infection With Potential Clinical Applications. Sci Rep. 2020 May 18;10(1):8159.

Title: Francia G, et al. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther. 2012 Mar;11(3):680-9.